Skip to main content

Advertisement

SpringerLink
Log in

The role of immune tolerance in preventing and treating arthritis

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

It has become increasingly clear that the innate and adaptive arms of the immune response cooperate in generating autoimmune damage in the pathogenesis of rheumatoid arthritis and juvenile idiopathic arthritis. Treatment targets the immunologic pathophysiology of the disease and is based on regaining immune tolerance. Recently introduced biological agents neutralize or simply block cytokines and their proinflammatory pathways, with favorable clinical outcome. However, major downsides are their lack of specificity and the need of continuous administration to be effective. Possibly, more can be gained from a specific approach. Indeed, recent findings suggest that targeting antigen-specific T cells can reinstate regulatory mechanisms and thus induce immune tolerization. This improved understanding has paved the way to novel immunotherapeutic approaches, some of which will be discussed here.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Petty RE, Southwood TR, Baum J, et al.: Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 1998, 25:1991–1994.

    PubMed  CAS  Google Scholar 

  2. Sakkas LI, Platsoucas CD: Immunopathogenesis of juvenile rheumatoid arthritis: role of T cells and MHC. Immunol Res 1995, 14:218–236.

    PubMed  CAS  Google Scholar 

  3. Salmon M, Gaston JS: The role of T-lymphocytes in rheumatoid arthritis. Br Med Bull 1995, 51:332–345.

    PubMed  CAS  Google Scholar 

  4. Matzinger P: Tolerance, danger, and the extended family. Ann Rev Immunol 1994, 12:991–1045.

    CAS  Google Scholar 

  5. Prinz JC: Disease mimicry—a pathogenetic concept for T cellmediated autoimmune disorders triggered by molecular mimicry? Autoimmun Rev 2004, 3:10–15.

    Article  PubMed  Google Scholar 

  6. Bonnin D, Prakken B, Samodal R, et al.: Ontogeny of synonymous T cell populations with specificity for a self MHC epitope mimicked by a bacterial homologoue: an antigenspecific T cell analysis in a non-transgenic system. Eur J Immunol 1999, 29:3826–3836.

    Article  PubMed  CAS  Google Scholar 

  7. Medzhitov R, Janeway C, Jr.: The toll receptor family and microbial recognition. Trends Microbiol 2000, 8:452–456.

    Article  PubMed  CAS  Google Scholar 

  8. Kimbrell DA, Beutler B: The evolution and genetics of innate immunity. Nat Rev Genet 2001, 2:256–267.

    Article  PubMed  CAS  Google Scholar 

  9. Aderem A, Ulevitch RJ: Toll-like receptors in the induction of the innate immune response. Nature 2000, 406:782–787.

    Article  PubMed  CAS  Google Scholar 

  10. Albani S, Ravelli A, Massa M, et al.: Immune responses to the Escherichia coli dnaJ heat shock protein in juvenile rheumatoid arthritis and their correlation with disease activity. J Pediatr 1994, 124:561–565.

    Article  PubMed  CAS  Google Scholar 

  11. Abulafia-Lapid R, Elias D, Raz I, et al.: T cell proliferative responses of type 1 Diabetes patients and healthy individuals to human hsp60 and its peptides. J Autoimmunity 1999, 12:121–129.

    Article  CAS  Google Scholar 

  12. de Graeff-Meeder ER, Zee R, Rijkers GT, et al.: Recognition of human 60 kD heat shock protein by mononuclear cells from patients with juvenile chronic arthritis. Lancet 1991, 337:1368–1372.

    Article  PubMed  Google Scholar 

  13. de Kleer IM, Kamphuis SM, Rijkers GT, et al.: The spontaneous remission of juvenile idiopathic arthritis is characterized by CD30+ T cells directed to human heat-shock protein 60 capable of producing the regulatory cytokine interleukin-10. Arthritis Rheum 2003, 48:2001–2010.

    Article  PubMed  CAS  Google Scholar 

  14. Prakken ABJ, Van Eden W, Rijkers GT, et al.: Autoreactivity to human heat-shock protein 60 predicts disease remission in oligoarticular juvenile rheumatoid arthritis. Arthritis Rheum 1996, 39:1826–1832.

    Article  PubMed  CAS  Google Scholar 

  15. Abbas AK: The control of T cell activation vs. tolerance. Autoimmun Rev 2003, 2:115–118.

    Article  PubMed  CAS  Google Scholar 

  16. Pasare C, Medzhitov R: Toll-like receptors: balancing host resistance with immune tolerance. Curr Opin Immunol 2003, 15:677–682. This paper describes the role of the receptors of the innate immune system on induction of an adaptive immune response. Also suggests a pathogenic role for malfunction of this pathway.

    Article  PubMed  CAS  Google Scholar 

  17. Nolan KF, Strong V, Soler D, et al.: IL-10-conditioned dendritic cells, decommissioned for recruitment of adaptive immunity, elicit innate inflammatory gene products in response to danger signals. J Immunol 2004, 172:2201–2209. This paper shows regulatory effects of an adaptive response on the innate immune system. A very good example of the crosstalk between the two arms of the immune system.

    PubMed  CAS  Google Scholar 

  18. La Cava A, Matarese G: The weight of leptin in immunity. Nat Rev Immunol 2004, 4:371–379.

    Article  PubMed  CAS  Google Scholar 

  19. Moreno C, Merino J, Vazquez B, et al.: Anti-inflammatory cytokines induce lipopolysaccharide tolerance in human monocytes without modifying toll-like receptor 4 membrane expression. Scand J Immunol 2004, 59:553–558.

    Article  PubMed  CAS  Google Scholar 

  20. Wolkers MC, Brouwenstijn N, Bakker AH, et al.: Antigen bias in T cell cross-priming. Science 2004, 304:1314–1317.

    Article  PubMed  CAS  Google Scholar 

  21. Tze LE, Baness EA, Hippen KL, Behrens TW: Ig light chain receptor editing in anergic B cells. J Immunol 2000, 165:6796–6802.

    PubMed  CAS  Google Scholar 

  22. Berg LJ: Generation of the T cell repertoire. Curr Opin Immunol 1989, 2:87–92.

    Article  PubMed  CAS  Google Scholar 

  23. Hammerling GJ, Schonrich G, Ferber I, Arnold B: Peripheral tolerance as a multi-stepmechanism. Immunol Rev 1993, 133:93–104.

    Article  PubMed  CAS  Google Scholar 

  24. Ohashi PS, Oehen S, Buerki K, et al.: Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 1991, 65:305–317.

    Article  PubMed  CAS  Google Scholar 

  25. Oldstone MB, Nerenberg M, Southern P, et al.: Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response. Cell 1991, 65:319–331.

    Article  PubMed  CAS  Google Scholar 

  26. Jonuleit H, Schmitt E, Stassen M, et al.: Identification and functional characterization of human CD4+CD25+ T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001, 193:1285–1294.

    Article  PubMed  CAS  Google Scholar 

  27. Bluestone JA, Abbas AK: Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003, 3:253–257. A major breakthrough in how Treg is thought of. Proposes the coexistance of two major subsets of Treg and discusses their development.

    Article  PubMed  CAS  Google Scholar 

  28. Giannini EH, Brewer EJ, Kuzmina N, et al.: Methotrexate in resistant juvenile rheumatoid arthritis. Results of the USAUSSR double-blind, placebo-controlled trial. N Engl J Med 1992, 326:1043–1049.

    Article  PubMed  CAS  Google Scholar 

  29. Han J, Ulevitch RJ: Emerging targets for anti-inflammatory therapy. Nat Cell Biol 1999, 1:E39-E40.

    Article  PubMed  CAS  Google Scholar 

  30. Ehrenstein MR, Evans JG, Singh A, et al.: Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004, 200:277–285. Interesting report suggesting that anti-TNFα therapy does not only suppress the inflammatory immune response, but also actively modulates the immune response.

    Article  PubMed  CAS  Google Scholar 

  31. Wendling D, Racadot E, Wijdenes J: Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 1993, 20:259–262.

    PubMed  CAS  Google Scholar 

  32. Nishimoto N, Kishimoto T, Yoshizaki K: Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann Rheum Dis 2000, 59(Suppl 1):i21-i27.

    Article  PubMed  CAS  Google Scholar 

  33. Nishimoto N, Yoshizaki K, Maeda K, et al.: Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol 2003, 30:1426–1435.

    PubMed  CAS  Google Scholar 

  34. Choy EH, Isenberg DA, Garrood T, et al.: Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, doseescalation trial. Arthritis Rheum 2002, 46:3143–3150.

    Article  PubMed  CAS  Google Scholar 

  35. Cutolo M: [IL-1Ra: its role in rheumatoid arthritis]. Reumatismo 2004, 56:41–45.

    PubMed  CAS  Google Scholar 

  36. Silverman GJ, Weisman S: Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 2003, 48:1484–1492.

    Article  PubMed  CAS  Google Scholar 

  37. Edwards JC, Szczepanski L, Szechinski J, et al.: Efficacy of Bcell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350:2572–2581.

    Article  PubMed  CAS  Google Scholar 

  38. De Vita S, Zaja F, Sacco S, et al.: Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum 2002, 46:2029–2033.

    Article  PubMed  CAS  Google Scholar 

  39. Schulze-Koops H, Davis LS, Haverty TP, et al.: Reduction of Th1cell activity in the peripheral circulation of patients with rheumatoid arthritis after treatment with a non-depleting humanized monoclonal antibody to CD4. J Rheumatol 1998, 25:2065–2076.

    PubMed  CAS  Google Scholar 

  40. Chatenoud L: CD3-specific antibody-induced active tolerance: from bench to bedside. Nat Rev Immunol 2003, 3:123–132.

    Article  PubMed  CAS  Google Scholar 

  41. Moreland LW, Alten R, Van den BF, et al.: Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 2002, 46:1470–1479.

    Article  PubMed  CAS  Google Scholar 

  42. Eagar TN, Karandikar NJ, Bluestone JA, Miller SD: The role of CTLA-4 in induction and maintenance of peripheral T cell tolerance. Eur J Immunol 2002, 32:972–981.

    Article  PubMed  CAS  Google Scholar 

  43. Weiner HL: Oral tolerance for the treatment of autoimmune diseases. Annu Rev Med 1997, 48:341–351.

    Article  PubMed  CAS  Google Scholar 

  44. Xiao BG, Link H: Mucosal tolerance: a two-edged sword to prevent and treat autoimmune diseases. Clin Immunol Immunopathol 1997, 85:119–128.

    Article  PubMed  CAS  Google Scholar 

  45. Barnett ML, Combitchi D, Trentham DE: A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis. Arthritis Rheum 1996, 39:623–628.

    Article  PubMed  CAS  Google Scholar 

  46. Myers LK, Higgins GC, Finkel TH, et al.: Juvenile arthritis and autoimmunity to type II collagen. Arthritis Rheum 2001, 44:1775–1781.

    Article  PubMed  CAS  Google Scholar 

  47. Steenbakkers PG, Baeten D, Rovers E, et al.: Localization of MHC class II/human cartilage glycoprotein-39 complexes in synovia of rheumatoid arthritis patients using complex-specific monoclonal antibodies. J Immunol 2003, 170:5719–5727.

    PubMed  CAS  Google Scholar 

  48. Baeten D, Steenbakkers PG, Rijnders AM, et al.: Detection of major histocompatibility complex/human cartilage gp-39 complexes in rheumatoid arthritis synovitis as a specific and independent histologic marker. Arthritis Rheum 2004, 50:444–451.

    Article  PubMed  CAS  Google Scholar 

  49. Steinman RM, Mellman I: Immunotherapy: bewitched, bothered, and bewildered no more. Science 2004, 305:197–200. This article provides an update on state-of-the-art immunotherapy in basic research and clinic. It also describes difficulties to overcome and where future research should be focused on.

    Article  PubMed  CAS  Google Scholar 

  50. Prakken B, Kuis W, Van Eden W, Albani S: Heat shock proteins in juvenile idiopathic arthritis: keys for understanding remitting arthritis and candidate antigens for immune therapy. Curr Rheumatol Rep 2002, 4:466–473.

    Article  PubMed  Google Scholar 

  51. Welch WJ, Kang HS, Beckmann RP, Mizzen LA: Response of mammalian cells to metabolic stress; changes in cell physiology and structure/function of stress proteins. Curr Top Microbiol Immunol 1991, 167:31–55.

    PubMed  CAS  Google Scholar 

  52. Jones DB, Coulson AFW, Duff GW: Sequence homologies between hsp60 and autoantigens. Immunol Today 1993, 14:115–118.

    Article  PubMed  CAS  Google Scholar 

  53. Albani S, Keystone EC, Nelson JL, et al.: Positive selection in autoimmunity: abnormal immune responses to a bacterial dnaJ antigenic determinant in patients with early rheumatoid arthritis. Nature Med 1995, 1:448–452.

    Article  PubMed  CAS  Google Scholar 

  54. Windhagen A, Nicholson LB, Weiner HL, et al.: Role of Th1 and Th2 cells in neurologic disorders. Chem Immunol 1996, 63:171–186.

    Article  PubMed  CAS  Google Scholar 

  55. Van Eden W, Thole JER, van der Zee R, et al.: Cloning of the mycobacterial epitope recognized by T lymphocytes in adjuvant arthritis. Nature 1988, 331:171–173.

    Article  PubMed  Google Scholar 

  56. Van Eden W: Heat-shock proteins as immunogenic bacterial antigens with the potential to induce and regulate autoimmune arthritis. Immunol Rev 1991, 121:5–28.

    Article  PubMed  Google Scholar 

  57. Albani S, Keystone EC, Nelson JL, et al.: Positive selection in autoimmunity: abnormal immune responses to a bacterial dnaJ antigenic determinant in patients with early rheumatoid arthritis. Nature Med 1995, 1:448–452.

    Article  PubMed  CAS  Google Scholar 

  58. La Cava A, Nelson JL, Ollier WER, et al.: Genetic bias in immune responses to a cassette shared by different microorganisms in patients with rheumatoid arthritis. J Clin Invest 1997, 100:658–663.

    Article  PubMed  Google Scholar 

  59. Prakken BJ, Samodal R, Le TD, et al.: Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Proc Natl Acad Sci U S A 2004, 101:4228–4233. Well designed phase I clinical trial that shows the ability of a mucosal route to induce tolerance to a specific antigen systemically. Most likely achieved by the induction of Treg.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine and Pediatrics, University of California, San Diego, 9500 Gilman Drive, 92093-0731, La Jolla, CA, USA

    Salvatore Albani MD, PhD

Authors
  1. Gijs Teklenburg MSC
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Salvatore Albani MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Teklenburg, G., Albani, S. The role of immune tolerance in preventing and treating arthritis. Curr Rheumatol Rep 6, 434–441 (2004). https://doi.org/10.1007/s11926-004-0022-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-004-0022-3

Keywords

Search

Navigation